Last updated on November 2017

A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Natroba™ (spinosad) for the Treatment of Scabies

Brief description of study

Clinical research study for the treatment of scabies.

Detailed Study Description

The main purpose of this study is to compare the safety, efficacy, and tolerability of a once-daily topical application of IDP-123 Lotion compared to the IDP-123 Vehicle Lotion in subjects with moderate to severe acne. Subjects must be at least 9 years of age or older and generally healthy. IDP-123 is a lotion containing 0.045% tazarotene for the topical treatment of acne. “Vehicle” is a term to describe a lotion that does not contain any active drug (similar to a placebo). If you decide to be in this research study, you may receive either the IDP-123 Lotion or the IDP-123 Vehicle Lotion. IDP-123 Lotion is called an investigational drug because it has not been approved for sale by the United States Food and Drug Administration (FDA). Because this is a research study, the topical study drug, IDP-123 Lotion, will be given to you only during this study and not after the study is over. 

Assignment to IDP-123 Lotion or IDP-123 Vehicle Lotion will be done randomly, by chance (like tossing a coin). You will have a 50% (1 out of 2) chance of receiving active study lotion and a 50% (1 out of 2) chance of receiving Vehicle Lotion. For this study, all study drug applications will be on the face. 

Participation will be approximately 28 days( including 3 in office visits)

You may receive up to $150.00 if you complete the whole study, as a compensation for your time and travel.


Clinical Study Identifier: TX154533

Contact Investigators or Research Sites near you

Start Over

Valerija Misev

Juva Skin and Laser Center
New York, NY USA
  Connect »